AZD9056 Relative Bioavailability Study

An Open-label, Randomized, 2 Cohort, 2 Period Crossover Study to Assess the Relative Bioavailability of the Phase III to the Phase IIb Formulation of AZD9056 in Healthy Male and Female Subjects

The aims of this study are to compare the blood levels achieved with a new formulation of AZD9056 to an existing formulation of AZD9056 used in previous studies.

Inclusion Criteria:

• Provision of informed consent prior to any study-specific procedures
• Healthy Volunteers, Females should not be of childbearing potential
• BMI between 18 and 30 kg/m2

Exclusion Criteria:

• Clinically significant ECG abnormality suggestive of underlying cardiovascular disease
• A history or presence of GI, hepatic or renal disease or other condition known to interfere with the absorption, distribution, metabolism and excretion of drugs
• Known or suspected drug or alcohol abuse or positive DOA test